Part 2 enrolled 3 patients and was a surgical study to determine plerixafor's penetration in tumor tissue.<b>Results:</b> In Part 1, no dose-limiting toxicities were seen at the maximum planned dose of plerixafor + bevacizumab.Treatment was well tolerated.
Erratum To: Circulating tumor markers: a guide to their appropriate clinical use ; Comparative summary of recommendations from clinical practice guidelines (PART 1) Gion M, Trevisiol C, Rutjes AW, Rainato G, Fabricio AS.Int J Biol Markers.2016 Dec 23;31(4):e332-e367. doi: 10.5301/jbm.5000251.
We sequenced core HR pathway genes in 12 pairs of pretreatment and postprogression tumor biopsy samples collected from patients in ARIEL2 Part 1, a phase II study of the PARPi rucaparib as treatment for platinum-sensitive, relapsed ovarian carcinoma.
Topics discussed in Part 1 of this review include computationally quantifying of tumor subpopulations; clone-based network modeling, cancer hallmark-based networks and their high-order rewiring principles and the principles of cell survival networks of fast-growing clones.
Cell production rates in human tissues and tumours and their significance. Part 1: an introduction to the techniques of measurement and their limitations.